{"id":"W2601626987","doi":"10.1200/jco.2012.30.15_suppl.5025","title":"Phase II trial of temsirolimus and bevacizumab for initial recurrence of endometrial cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Credit Valley Hospital","funders":"","keywords":"Medicine; Bevacizumab; Temsirolimus; Internal medicine; Regimen; Endometrial cancer; Oncology; Progression-free survival; Interim analysis; Surgery; Clinical trial; Cancer; Chemotherapy; Discovery and development of mTOR inhibitors","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002385855,0.001104201,0.001588109,0.0004502396,0.0002983499,0.0006701895,0.0006815019,0.001078157,0.005111068],"category_scores_gemma":[0.001248521,0.0005340051,0.000884839,0.0003002572,0.0005316429,0.0003789654,0.0003694274,0.002145012,0.000931324],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005632792,"about_ca_system_score_gemma":0.00148345,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005686407,"about_ca_topic_score_gemma":0.002035377,"domain_scores_codex":[0.9994361,0.0003370309,0.00002974915,0.00006264279,0.00004320281,0.00009113377],"domain_scores_gemma":[0.9993532,0.0001381513,0.0001338992,0.00004609665,0.00003152738,0.0002970361],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8856692,0.01915359,0.003844024,0.0007295636,0.000959911,0.0001928412,0.0001451019,0.001182203,0.01514389,0.0003174556,0.003979313,0.06868284],"study_design_scores_gemma":[0.7904987,0.1985846,0.00510815,0.00003814728,0.0003376818,0.0001435813,0.00001825259,0.0007495079,0.001528551,0.0001275135,0.002852598,0.00001271718],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9752582,0.005623042,0.001293791,0.0009964603,0.0003503129,0.01039344,0.001604601,0.0001621746,0.004318085],"genre_scores_gemma":[0.9728343,0.001839222,0.00419871,0.0017216,0.0002759236,0.009990405,0.003122428,0.00003081057,0.005986648],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005111068,"threshold_uncertainty_score":0.01709825,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2899490102339264,"score_gpt":0.566544020402582,"score_spread":0.2765950101686556,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}